An in vivo base editing approach targeting the PRNP gene led to a 52% increase in the lifespan of mouse models inoculated with the most common sporadic and genetic types of human pathogenic prion ...

Abelacimab, a factor XI inhibitor, demonstrated a 62–69% reduction in major bleeding compared to rivaroxaban in atrial fibrillation patients at moderate-to-high stroke risk, with comparable safety and ...

These documents have become too technical, too inconsistent, and rely too much on expert opinion, Marco Valgimigli argues.

Cardiovascular management strategies are essential to individuals with chronic lymphocytic leukemia (CLL) or multiple myeloma (MM) undergoing active treatment, due to the high rate of atrial ...

Clinically significant reductions in bleeding underscore abelacimab’s strong potential to address an unmet need for patients ...

The true incidence of thrombosis among people who received targeted therapy for breast cancer is significantly higher than ...

CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announces it has engaged ...

Dr. Suresh Vedantham asks Drs. Pavan Kavali and Kristen Sanfilippo about possible benefits of a DVT response team model, ...

The knowns and unknowns about venous thrombus biology as it relates to in-stent restenosis and how these results drive ...

Report on how AI is driving market transformation - The global heparin market size is estimated to grow by USD 3.34 billion ...